European Investor
05 Aug 2025, 18:33
Axsome Therapeutics Reports 72% Surge in Q2 Revenue, Driven by AUVELITY and SUNOSI Growth
Axsome Therapeutics (NASDAQ: AXSM) posted strong second-quarter results, with net product revenue rising 72% year-over-year to $150 million, driven by robust demand for its CNS treatments.
AUVELITY led the gains with Q2 sales of $119.6 million, up 84% year-over-year, while SUNOSI posted $30 million in revenue, up 35%. Newly launched SYMBRAVO, approved for migraines, contributed $0.4 million in its debut quarter.
CEO Herriot Tabuteau highlighted advancing regulatory milestones, including plans to submit new drug applications for AXS-05 in Alzheimer’s agitation (Q3) and AXS-12 for narcolepsy (Q4). Despite a $48 million net loss, down from $79.3 million a year ago, Axsome reaffirmed its cash runway into profitability, with $303 million in reserves as of June 30.
Axsome Therapeutics (NASDAQ: AXSM) posted strong second-quarter results, with net product revenue rising 72% year-over-year to $150 million, driven by robust demand for its CNS treatments.
AUVELITY led the gains with Q2 sales of $119.6 million, up 84% year-over-year, while SUNOSI posted $30 million in revenue, up 35%. Newly launched SYMBRAVO, approved for migraines, contributed $0.4 million in its debut quarter.
CEO Herriot Tabuteau highlighted advancing regulatory milestones, including plans to submit new drug applications for AXS-05 in Alzheimer’s agitation (Q3) and AXS-12 for narcolepsy (Q4). Despite a $48 million net loss, down from $79.3 million a year ago, Axsome reaffirmed its cash runway into profitability, with $303 million in reserves as of June 30.
